HE HELP Cango Inc. Loading... : Investor Sentiment and Bull/Bear Views

The author already owns the stock and says they are a buyer of more after the pullback from the $12.50 high, citing large insider purchases and insider ownership as skin in the game. They note $175 million of cash as of 6/30 to fund commercialization if approved, and speculate that political interest in treating US veterans with psychoactive drugs could produce a supportive statement. They call it a strong buy below $10 and cite the Canadian government's popularity as a secondary positive.

The author states they are insanely bullish on $HELP and have already 6x'd their position using call options. The rationale is that several of the company's drugs are in late-stage trials, and the street anticipates a breakthrough with large upside price targets. The main risk implied is that the thesis depends on trial outcomes and analyst expectations materializing.

The author claims Cybin (HELP) is highly undervalued relative to other psychedelic stocks and that Phase 3 data due in about a month is the catalyst for a price surge ahead of any CMPS approval. The rationale is that its deuterated psilocybin is more stable and predictable, requiring only 3-hour sessions twice a year versus Spravato's twice-weekly sessions, and that its Phase 3 trial design mirrors the CMPS trial that received FDA breakthrough designation in Phase 2. The stated catalyst is the imminent Phase 3 readout, with the implied horizon of roughly one month. No specific downside risk is stated beyond the general dependence on trial results.